Clinical trial NCT04917393: Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive
Official title: Multi-Organ Denervation to RedUce Sympathetic Drive, Multi-Center, Prospective Feasibility Study - The MODUS ON MED Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypertension
Type 2 Diabetes
Metabolic Syndrome
Keywords: Renal Denervation
Hepatic Denervation
Lead sponsor: Metavention
Sponsor class: INDUSTRY
First posted: 2021-06-08
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: The study is a prospective, single-arm, multi-center, sham controlled feasibility study
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The objective of the study is to evaluate the safety of multi-organ denervation using the Integrated Radio Frequency (iRF) Denervation System. and to understand any potential improvement in hypertension and glycemic control.

Detailed description: This study is a prospective, single-arm, multi-center, sham contollred trial to evaluate the initial safety and performance of multi-organ denervation for the treatment of hypertension and type 2 diabetes.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 and ≤ 80 years old
2. Office systolic blood pressure (SBP) ≥ 135 mmHg or on a stable dose of antihypertensive medication(s) for at least 30 days
3. Documented daytime systolic ambulatory blood pressure (ABP) ≥ 135 and \< 175 mmHg
4. HbA1c ≥7.5% - ≤11.0% on a stable dose of antidiabetic medication(s) for at least 90 days
5. Waist circumference ≥ 102 cm (male) and ≥ 88 cm (female)

   Exclusion Criteria:
6. Renal artery (RA) anatomy on either side OR common hepatic artery (CHA) anatomy, ineligible for treatment including the following:

   1. CHA OR RA artery diameter \< 4.0 mm or \> 7.0 mm
   2. CHA or RA length that does not allow adequate landing zone for at least one iRF balloon placement and treatment
   3. Only one functioning kidney
   4. Presence of abnormal kidney tumors
   5. CHA or RA with aneurysm
   6. Pre-existing stent or history of angioplasty in target arteries
   7. Fibromuscular dysplasia of the CHA or renal arteries
   8. Presence of CHA OR RA diameter stenosis \>30%
   9. Individual lacks appropriate arterial anatomy for treatment or for maneuvering of the device from the femoral artery to the target location(s)
7. Prior renal denervation procedure
8. Type 1 diabetes mellitus
9. Use of insulin within 90 days prior to Index Procedure
10. eGFR \< 45 mL/min per 1.73 m2
11. One or more documented severe hypertensive crisis (persistent or elevated hypertension \> 180 mmHg accompanied by clinical symptoms) in the 90 days prior to Index Procedure
12. One or more documented hyperglycemia episodes (requiring hospitalization) in the 90 days prior to Index Procedure
13. One or more Severe hypoglycemic events (severe cognitive impairment requiring external assistance for recovery) in the 90 days prior to Index Procedure
14. Evidence of active infection within 7 days prior to Index Procedure
15. Documented history of chronic active inflammatory bowel disorders such as Crohn's disease or ulcerative colitis
16. Any history of cerebrovascular event (e.g., stroke, transient ischemic event, and cerebrovascular accident) within 6 months prior to Index Procedure
17. Myocardial infarction within 6 months of Index Procedure
18. Heart failure (New York Heart Association \[NYHA\] Class III-IV) at time of consent.
19. Documented confirmed episode(s) of stable or unstable angina within 6 months prior to Index Procedure
20. Documented history of persistent or permanent atrial tachyarrhythmia
21. Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
22. Night shift workers
23. Chronic regular use (e.g., daily use) of NSAIDs for 6 months or greater. Aspirin therapy is allowed.
24. Active implantable medical device (e.g., ICD or CRT-D, neuromodulator/spinal stimulator, baroreflex stimulator)
25. Known Primary pulmonary hypertension (HTN) (\> 60 mmHg pulmonary artery or right ventricular systolic pressure)
26. Individual has known pheochromocytoma, Cushing syndrome, primary hyperaldosteronism, coarctation of the aorta, untreated hyperthyroidism, untreated hypothyroidism, or primary hyperparathyroidism. (Note: Treated hyperthyroidism and treated hypothyroidism are permissible.)
27. A history of bariatric surgery, baroreflex activation therapy, or liver transplant, or these procedures are planned in the 365 days following Index Procedure
28. Previous hepatobiliary surgery/intervention that in the opinion of the investigator could preclude the ability to perform denervation of the CHA
29. History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)
30. ALT or AST greater than 200 U/L
31. History or evidence of active / suspected chronic liver or biliary disease including Hepatitis B, Hepatitis C, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis, Wilson's disease, alpha-1-antitrypsin deficiency, hemochromatosis, drug-induced liver disease, bile duct dilation and obstruction, symptomatic gallstones, liver cancer or liver cirrhosis. Note: subjects with past symptomatic gallstones and a cholecystectomy are not excluded.
32. Current or chronic pancreatitis
33. Documented contraindication or allergy to contrast medium not amenable to treatment
34. Limited life expectancy of \< 1 year at the discretion of the investigator
35. Any known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or for any reason in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements or whose participation may result in data analysis confounders
36. Pregnant, nursing, or planning to become pregnant (documented negative pregnancy test result required documented within a maximum of 7 days before Index Procedure for all women of childbearing potential)
37. Concurrent enrollment in any other investigational drug or device trial (participation in noninterventional registries is acceptable)

Primary outcomes:
measure: Rate of SADEs
timeFrame: Index Procedure through 30 days.
Secondary outcomes:
measure: Change in automated unobserved average office blood pressure
timeFrame: 90, 180 and 365 days
measure: Change in Systolic/Diastolic Blood Pressure - Ambulatory Blood Pressure Monitoring
timeFrame: 90, 180 and 365 days
measure: Change in Glycemic control - HbA1c
timeFrame: 90 days, 180 days and 365 days
measure: Change in Glycemic control - fasting glucose
timeFrame: 90 days, 180 days and 365 days
Other outcomes:
Locations:
city: Tbilisi
country: Georgia
facility: Israeli-Georgian Medical Research Clinic Helsicore
city: Tbilisi
country: Georgia
facility: Tbilisi Heart and Vascular Clinic
Study officials:
References: